Long-term analysis of phase 2 GeparNuevo (174 patients, early triple-negative breast cancer): adding durvalumab vs placebo to neoadjuvant chemotherapy improved invasive disease-free survival (HR 0.56) and overall survival (HR 0.33) at median 86.4 months' follow-up.
RCTn = 174
Loibl et al. Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial